TERN
Terns·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TERN
Terns Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops small-molecule products for serious diseases, including oncology, obesity and NASH
1065 East Hillsdale Blvd., Suite 100, Foster City, California 94404
--
Terns Pharmaceuticals, Inc., was incorporated under the laws of the Cayman Islands on December 9, 2016. On December 29, 2020, the Company was deregistered under the Cayman Islands Corporation Law (2020 Revision) and naturalized under Section 388 of the Delaware General Corporation Law (by filing a certificate of naturalization with the Secretary of State of Delaware), pursuant to which its jurisdiction of incorporation was changed from Cayman Islands to Delaware, TernsPharmaceuticals Inc., a clinical-stage biopharmaceutical company, Develop a range of small molecule product candidates to address serious diseases, including oncology and obesity.
Company Financials
EPS
TERN has released its 2025 Q3 earnings. EPS was reported at -0.27, versus the expected -0.3, beating expectations. The chart below visualizes how TERN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
